Lipid nanocapsules for dermal application: A comparative study of lipid-based versus polymer-based nanocarriers

Lipid nanocarriers are efficient transdermal drug delivery systems while polymeric nanoparticles are better suited for local effects on the skin. Lipid nanocapsules (LNC) are colloidal carriers providing controlled release profiles and improved bioavailability for many drug substances and diverse ad...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of pharmaceutics and biopharmaceutics Vol. 79; no. 1; pp. 36 - 42
Main Authors:	Abdel-Mottaleb, Mona M.A., Neumann, Dirk, Lamprecht, Alf
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.09.2011
Subjects:	Administration, Cutaneous Animals Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - analysis Anti-Inflammatory Agents, Non-Steroidal - chemistry Anti-Inflammatory Agents, Non-Steroidal - pharmacology Cellulose - analogs & derivatives Cellulose - chemistry Delayed-Action Preparations Drug Carriers - chemistry Drug Compounding Drug Delivery Systems Drug Evaluation, Preclinical Ear - physiology Ibuprofen - administration & dosage Ibuprofen - analysis Ibuprofen - chemistry Ibuprofen - pharmacology Lipid nanocapsules Lipids - chemistry Nanocapsules - chemistry Nanocarriers Nanoparticles - chemistry Nanostructures - chemistry Particle Size Permeability Polyethylene Glycols - chemistry Polymer nanoparticles Polymers - chemistry Skin Skin - metabolism Stearic Acids - chemistry Surface-Active Agents - chemistry Swine Transdermal Polymer nanoparticles Skin Transdermal Lipid nanocapsules Nanocarriers
ISSN:	0939-6411, 1873-3441, 1873-3441
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Lipid nanocarriers are efficient transdermal drug delivery systems while polymeric nanoparticles are better suited for local effects on the skin. Lipid nanocapsules (LNC) are colloidal carriers providing controlled release profiles and improved bioavailability for many drug substances and diverse administration routes. However, they have not been explored before for transdermal application. Here, we study the behavior of LNC as a transdermal drug delivery system using ibuprofen as a model drug. A comparison to other lipid nanocarriers such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) and polymeric nanocarriers has been made. It was found that LNC could increase the flux rate of ibuprofen 21.9 ± 0.5 compared to 5.8 ± 0.4 μg/cm 2 h in case of drug solution. Similar flux rates were obtained for SLN and NLC with average values of 22.9 ± 0.5 and 22.5 ± 2.0 μg/cm 2 h, respectively. On the other side, comparison to polymeric nanoparticles showed that the polymer-based carriers of the same particle size had lower permeation-enhancing effect with a flux rate of 10.62 ± 1.84 μg/cm 2 h. Polymeric carriers had fourfold higher accumulation in the skin compared to that of the LNC and twice the accumulation of SLN and NLC. These results would suggest that the LNC can be considered as efficient as SLN and NLC for the transdermal drug delivery while polymeric nanoparticles are more suitable for localized drug delivery to the skin.
AbstractList	Lipid nanocapsules (LNC) are colloidal carriers providing controlled release profiles and improved bioavailability for many drug substances and diverse administration routes. However, they have not been explored before for transdermal application. Here, we study the behavior of LNC as a transdermal drug delivery system using ibuprofen as a model drug. A comparison to other lipid nanocarriers such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) and polymeric nanocarriers has been made. It was found that LNC could increase the flux rate of ibuprofen 21.9±0.5 compared to 5.8±0.4 μg/cm(2)h in case of drug solution. Similar flux rates were obtained for SLN and NLC with average values of 22.9±0.5 and 22.5±2.0 μg/cm(2)h, respectively. On the other side, comparison to polymeric nanoparticles showed that the polymer-based carriers of the same particle size had lower permeation-enhancing effect with a flux rate of 10.62±1.84 μg/cm(2)h. Polymeric carriers had fourfold higher accumulation in the skin compared to that of the LNC and twice the accumulation of SLN and NLC. These results would suggest that the LNC can be considered as efficient as SLN and NLC for the transdermal drug delivery while polymeric nanoparticles are more suitable for localized drug delivery to the skin. Lipid nanocapsules (LNC) are colloidal carriers providing controlled release profiles and improved bioavailability for many drug substances and diverse administration routes. However, they have not been explored before for transdermal application. Here, we study the behavior of LNC as a transdermal drug delivery system using ibuprofen as a model drug. A comparison to other lipid nanocarriers such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) and polymeric nanocarriers has been made. It was found that LNC could increase the flux rate of ibuprofen 21.9±0.5 compared to 5.8±0.4 μg/cm(2)h in case of drug solution. Similar flux rates were obtained for SLN and NLC with average values of 22.9±0.5 and 22.5±2.0 μg/cm(2)h, respectively. On the other side, comparison to polymeric nanoparticles showed that the polymer-based carriers of the same particle size had lower permeation-enhancing effect with a flux rate of 10.62±1.84 μg/cm(2)h. Polymeric carriers had fourfold higher accumulation in the skin compared to that of the LNC and twice the accumulation of SLN and NLC. These results would suggest that the LNC can be considered as efficient as SLN and NLC for the transdermal drug delivery while polymeric nanoparticles are more suitable for localized drug delivery to the skin.Lipid nanocapsules (LNC) are colloidal carriers providing controlled release profiles and improved bioavailability for many drug substances and diverse administration routes. However, they have not been explored before for transdermal application. Here, we study the behavior of LNC as a transdermal drug delivery system using ibuprofen as a model drug. A comparison to other lipid nanocarriers such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) and polymeric nanocarriers has been made. It was found that LNC could increase the flux rate of ibuprofen 21.9±0.5 compared to 5.8±0.4 μg/cm(2)h in case of drug solution. Similar flux rates were obtained for SLN and NLC with average values of 22.9±0.5 and 22.5±2.0 μg/cm(2)h, respectively. On the other side, comparison to polymeric nanoparticles showed that the polymer-based carriers of the same particle size had lower permeation-enhancing effect with a flux rate of 10.62±1.84 μg/cm(2)h. Polymeric carriers had fourfold higher accumulation in the skin compared to that of the LNC and twice the accumulation of SLN and NLC. These results would suggest that the LNC can be considered as efficient as SLN and NLC for the transdermal drug delivery while polymeric nanoparticles are more suitable for localized drug delivery to the skin. Lipid nanocarriers are efficient transdermal drug delivery systems while polymeric nanoparticles are better suited for local effects on the skin. Lipid nanocapsules (LNC) are colloidal carriers providing controlled release profiles and improved bioavailability for many drug substances and diverse administration routes. However, they have not been explored before for transdermal application. Here, we study the behavior of LNC as a transdermal drug delivery system using ibuprofen as a model drug. A comparison to other lipid nanocarriers such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) and polymeric nanocarriers has been made. It was found that LNC could increase the flux rate of ibuprofen 21.9 ± 0.5 compared to 5.8 ± 0.4 μg/cm 2 h in case of drug solution. Similar flux rates were obtained for SLN and NLC with average values of 22.9 ± 0.5 and 22.5 ± 2.0 μg/cm 2 h, respectively. On the other side, comparison to polymeric nanoparticles showed that the polymer-based carriers of the same particle size had lower permeation-enhancing effect with a flux rate of 10.62 ± 1.84 μg/cm 2 h. Polymeric carriers had fourfold higher accumulation in the skin compared to that of the LNC and twice the accumulation of SLN and NLC. These results would suggest that the LNC can be considered as efficient as SLN and NLC for the transdermal drug delivery while polymeric nanoparticles are more suitable for localized drug delivery to the skin.
Author	Abdel-Mottaleb, Mona M.A. Neumann, Dirk Lamprecht, Alf
Author_xml	– sequence: 1 givenname: Mona M.A. surname: Abdel-Mottaleb fullname: Abdel-Mottaleb, Mona M.A. email: mona_abdelmottaleb@yahoo.com, alf.lamprecht@uni-bonn.de organization: Laboratory of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Bonn, Germany – sequence: 2 givenname: Dirk surname: Neumann fullname: Neumann, Dirk organization: Laboratory of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Bonn, Germany – sequence: 3 givenname: Alf surname: Lamprecht fullname: Lamprecht, Alf organization: Laboratory of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Bonn, Germany
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/21558002$$D View this record in MEDLINE/PubMed
BookMark	eNp9kUuL3DAQhEXYkJ3d5A_kEHTLyU63LdtyyGVZ8oKBXJKz0KMNGmzLkeyB-ffR7MxecthTo-76ClR1x27mMBNj7xFKBGw_HUo6LKasALEEUQL0r9gOZVcXtRB4w3bQ133RCsRbdpfSAQBE18g37LbCppEA1Y6FvV-847Oeg9VL2kZKfAiRO4qTHrleltFbvfowf-YP3IZp0TE_j8TTurkTDwMfzw6F0YkcP1JMW-JLGE8TxevyYh6jz8e37PWgx0TvrvOe_fn29ffjj2L_6_vPx4d9YUWFayGr3lbCdkAGGpLYiFpAZxptTf4gogFXDeBs3XZatLYWWLdCGpMvRiK6-p59vPguMfzdKK1q8snSOOqZwpaUlE0PfYtNVn64KjczkVNL9JOOJ_WcURbIi8DGkFKkQVm_PkWyRu1HhaDOdaiDOtehznUoECrXkdHqP_TZ_UXoywWinM8xh6aS9TRbcj6SXZUL_iX8H7_-pGU
CitedBy_id	crossref_primary_10_1016_j_jconrel_2014_05_054 crossref_primary_10_1016_j_jddst_2019_101148 crossref_primary_10_1208_s12248_013_9550_y crossref_primary_10_1016_j_ijpharm_2021_121114 crossref_primary_10_3109_1061186X_2013_769106 crossref_primary_10_1016_j_ijpharm_2023_122727 crossref_primary_10_1080_02652048_2025_2490033 crossref_primary_10_3390_pharmaceutics15030841 crossref_primary_10_1038_srep13065 crossref_primary_10_1007_s13346_024_01528_7 crossref_primary_10_1126_sciadv_1500439 crossref_primary_10_1016_j_ejpb_2012_06_006 crossref_primary_10_1016_j_biopha_2018_04_055 crossref_primary_10_1016_j_ijpharm_2016_11_023 crossref_primary_10_1016_j_jddst_2020_101605 crossref_primary_10_1016_j_jddst_2019_101309 crossref_primary_10_1016_j_bcab_2023_102858 crossref_primary_10_1038_s41598_022_16592_7 crossref_primary_10_1016_j_ejps_2017_12_024 crossref_primary_10_1111_ics_12397 crossref_primary_10_1155_2011_571272 crossref_primary_10_1016_j_colsurfb_2019_05_057 crossref_primary_10_1080_17425247_2020_1813107 crossref_primary_10_1002_jps_23282 crossref_primary_10_1016_j_jconrel_2022_06_027 crossref_primary_10_1002_jps_24494 crossref_primary_10_1016_S1734_1140_12_70901_5 crossref_primary_10_1208_s12249_023_02504_z crossref_primary_10_4155_tde_2023_0033 crossref_primary_10_1007_s11095_012_0888_0 crossref_primary_10_1021_acsomega_5c00046 crossref_primary_10_4155_tde_12_10 crossref_primary_10_1021_acsomega_5c01813 crossref_primary_10_3390_pharmaceutics13030328 crossref_primary_10_1007_s42250_024_01088_w crossref_primary_10_1016_j_ijpharm_2021_120640 crossref_primary_10_3390_polym13050826 crossref_primary_10_1016_j_ejps_2015_08_016 crossref_primary_10_1016_j_ijpharm_2022_122388 crossref_primary_10_1517_17425247_2012_686490 crossref_primary_10_1016_j_ejps_2016_05_005 crossref_primary_10_1016_j_ejpb_2015_06_020 crossref_primary_10_1016_j_ejpb_2017_02_001 crossref_primary_10_1016_j_xphs_2016_06_025 crossref_primary_10_1016_j_ijpharm_2015_08_050 crossref_primary_10_1016_j_plipres_2016_08_005 crossref_primary_10_1208_s12249_018_1087_z crossref_primary_10_1002_pts_2121 crossref_primary_10_3390_nano11123440 crossref_primary_10_3390_pharmaceutics15030927 crossref_primary_10_1016_j_jconrel_2022_01_019 crossref_primary_10_1080_03639045_2017_1391838 crossref_primary_10_1016_j_jconrel_2012_05_011 crossref_primary_10_1016_j_ejpb_2016_07_016 crossref_primary_10_1208_s12249_024_02831_9 crossref_primary_10_1007_s11051_020_05031_1 crossref_primary_10_1080_10717544_2020_1754527 crossref_primary_10_1016_j_ijpharm_2019_118886 crossref_primary_10_1016_j_molliq_2021_117145 crossref_primary_10_2174_0115748855297829240227072642 crossref_primary_10_1016_j_ejpb_2015_05_005 crossref_primary_10_2174_1574885513666181112153213 crossref_primary_10_1016_j_jddst_2020_101929 crossref_primary_10_1016_j_ijpharm_2020_119126 crossref_primary_10_1080_10717544_2022_2081383 crossref_primary_10_3390_pharmaceutics15030750 crossref_primary_10_1016_S2221_1691_12_60248_2 crossref_primary_10_1016_j_ejpb_2014_03_009 crossref_primary_10_1016_j_ejps_2025_107049 crossref_primary_10_2174_1381612827666210820095330 crossref_primary_10_1016_j_ejps_2018_05_016 crossref_primary_10_1016_j_jddst_2020_102104 crossref_primary_10_1007_s12094_012_0982_0 crossref_primary_10_1016_j_ejpb_2015_09_007 crossref_primary_10_1371_journal_pone_0246760 crossref_primary_10_1016_j_ijpharm_2021_120289 crossref_primary_10_1016_j_ijpharm_2025_125664 crossref_primary_10_1016_j_ijbiomac_2024_138895 crossref_primary_10_1016_j_vibspec_2022_103407 crossref_primary_10_3390_pharmaceutics15071927 crossref_primary_10_1016_j_ijpharm_2013_09_019 crossref_primary_10_1016_j_ejpb_2016_01_002 crossref_primary_10_1016_j_snb_2024_135549 crossref_primary_10_1016_j_jconrel_2022_05_048 crossref_primary_10_1049_iet_nbt_2019_0035 crossref_primary_10_1016_j_mtbio_2025_102220 crossref_primary_10_1038_srep42432 crossref_primary_10_1016_j_carbpol_2021_118238 crossref_primary_10_1016_j_ejps_2025_107034 crossref_primary_10_1186_s12929_024_01102_w crossref_primary_10_3389_fmed_2022_1017126 crossref_primary_10_3390_pharmaceutics15020490 crossref_primary_10_2217_nnm_14_74 crossref_primary_10_1002_jps_24152 crossref_primary_10_1080_10717544_2020_1716878 crossref_primary_10_1080_17425247_2016_1182490 crossref_primary_10_4155_tde_2017_0075 crossref_primary_10_3390_ph17040485 crossref_primary_10_4155_tde_2016_0027 crossref_primary_10_1016_j_ijpharm_2021_121080 crossref_primary_10_1016_j_addr_2012_06_010
Cites_doi	10.1016/j.ijpharm.2006.06.012 10.1016/S0168-3659(02)00258-4 10.1023/A:1018981515480 10.1016/j.addr.2007.04.006 10.1016/j.jconrel.2007.11.001 10.2174/1567201052772915 10.1159/000029940 10.1007/s11095-006-9662-5 10.1016/S0378-5173(00)00665-7 10.1016/0005-2736(95)00100-H 10.1007/s11095-006-0022-2 10.1016/j.biomaterials.2007.05.014 10.1016/S0378-5173(00)00402-6 10.1016/j.addr.2007.04.004 10.1159/000029928 10.1016/S0168-3659(01)00290-5 10.1016/j.jconrel.2008.05.027 10.1016/j.jconrel.2004.11.020 10.1016/j.addr.2003.10.028 10.1023/A:1016121319668 10.1016/j.addr.2007.04.012 10.1016/j.jconrel.2004.11.013 10.1016/j.ijpharm.2007.10.037 10.1016/S0169-409X(02)00114-X 10.1016/j.ejpb.2009.03.002 10.1016/j.jconrel.2006.02.014 10.1021/la901565q 10.1159/000056328 10.1007/s11095-009-9915-1 10.1038/nrd1304 10.1016/j.ijpharm.2004.03.018 10.1016/S0378-5173(01)00805-5 10.1016/j.ijpharm.2008.07.017
ContentType	Journal Article
Copyright	2011 Elsevier B.V. Copyright © 2011 Elsevier B.V. All rights reserved.
Copyright_xml	– notice: 2011 Elsevier B.V. – notice: Copyright © 2011 Elsevier B.V. All rights reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.ejpb.2011.04.009
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1873-3441
EndPage	42
ExternalDocumentID	21558002 10_1016_j_ejpb_2011_04_009 S0939641111001512
Genre	Journal Article Comparative Study
GroupedDBID	--- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO AAYOK ABFNM ABFRF ABGSF ABJNI ABMAC ABUDA ABXDB ABYKQ ABZDS ACDAQ ACGFO ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SES SEW SPCBC SSP SSU SSZ T5K TEORI UNMZH ~G- 9DU AATTM AAXKI AAYWO AAYXX ABWVN ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD AGCQF AGRNS BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8
ID	FETCH-LOGICAL-c421t-829c24c70eb05e81543407b5acb18711b0d2f0dc367a46c3413648bb11bb811d3
ISICitedReferencesCount	144
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000295427600006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0939-6411 1873-3441
IngestDate	Sat Sep 27 20:05:16 EDT 2025 Mon Jul 21 05:54:33 EDT 2025 Sat Nov 29 02:14:15 EST 2025 Tue Nov 18 21:51:48 EST 2025 Fri Feb 23 02:28:02 EST 2024
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Polymer nanoparticles Skin Transdermal Lipid nanocapsules Nanocarriers
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2011 Elsevier B.V. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c421t-829c24c70eb05e81543407b5acb18711b0d2f0dc367a46c3413648bb11bb811d3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
PMID	21558002
PQID	885909615
PQPubID	23479
PageCount	7
ParticipantIDs	proquest_miscellaneous_885909615 pubmed_primary_21558002 crossref_citationtrail_10_1016_j_ejpb_2011_04_009 crossref_primary_10_1016_j_ejpb_2011_04_009 elsevier_sciencedirect_doi_10_1016_j_ejpb_2011_04_009
PublicationCentury	2000
PublicationDate	2011-09-01
PublicationDateYYYYMMDD	2011-09-01
PublicationDate_xml	– month: 09 year: 2011 text: 2011-09-01 day: 01
PublicationDecade	2010
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	European journal of pharmaceutics and biopharmaceutics
PublicationTitleAlternate	Eur J Pharm Biopharm
PublicationYear	2011
Publisher	Elsevier B.V
Publisher_xml	– name: Elsevier B.V
References	Peltier, Oger, Lagarce, Couet, Benoit (b0040) 2006; 23 Radomska-Soukharev (b0085) 2007; 59 Schmook, Meingassner, Billich (b0115) 2001; 215 Zellmer, Pfiel, Lasch (b0145) 1995; 237 Moser, Kriwet, Kalia, Guy (b0155) 2001; 73 Cleek, Bunge (b0165) 1993; 10 Li, Nie, Kong, Li, Ju, Pan (b0095) 2008; 363 Béduneau, Hindré, Clavreul, Leroux, Saulnier, Benoit (b0050) 2008; 126 Casadei, Cerreto, Cesa, Giannuzzo, Feeney, Marianecci, Paolicelli (b0090) 2006; 325 Bouwstra, Honeywell-Nguyen (b0010) 2002; 54 Wu, Biatry, Cazeneuve, Guy (b0160) 2009; 26 Benech-Kieffer, Wegrich, Schwarzenbach, Klecak, Weber, Leclaire, Schaefer (b0110) 2000; 13 Beduneau, Saulnier, Hindre, Clavreulb, Lerouxc, Benoit (b0065) 2007; 28 Cevc (b0015) 2004; 56 Heurtault, Saulnier, Pech, Proust, Benoit (b0025) 2002; 19 Müller, Petersen, Hommoss, Pardeike (b0080) 2007; 59 Prausnitz, Mitragotri, Langer (b0020) 2004; 3 Shokri, Nokhodchi, Dashbolaghi, Hassan-Zadeh, Ghafourian, Barzegar Jalali (b0125) 2001; 228 Hadgraft, Valenta (b0120) 2000; 200 Lamprecht, Saumet, Roux, Benoit (b0035) 2004; 278 Simon, Maibach (b0105) 2000; 13 Zhao, Moddaresi, Jones, Brown (b0135) 2009; 72 Sinico, Manconi, Peppi, Lai, Valenti, Fadda (b0150) 2005; 103 Lamprecht, Bouligand, Benoit (b0030) 2002; 84 Benson (b0130) 2005; 2 Lamprecht, Benoit (b0060) 2006; 112 Schäfer-Korting, Mehnert, Korting (b0075) 2007; 59 Jacobi, Taube, Schäfer, Sterry, Lademann (b0100) 2005; 103 Anton, Saulnier, Gaillard, Porcher, Vrignaud, Benoit (b0070) 2009; 25 Allard, Passirani, Garcion, Pigeon, Vessières, Jaouen, Benoit (b0045) 2008; 130 Khalid, Simard, Hoarau, Dragomir, Leroux (b0055) 2006; 23 Georgetti, Casagrande, Verri, Lopez, Fonseca (b0005) 2008; 352 Zhai, Maibach (b0140) 2001; 14 Georgetti (10.1016/j.ejpb.2011.04.009_b0005) 2008; 352 Li (10.1016/j.ejpb.2011.04.009_b0095) 2008; 363 Schmook (10.1016/j.ejpb.2011.04.009_b0115) 2001; 215 Casadei (10.1016/j.ejpb.2011.04.009_b0090) 2006; 325 Jacobi (10.1016/j.ejpb.2011.04.009_b0100) 2005; 103 Sinico (10.1016/j.ejpb.2011.04.009_b0150) 2005; 103 Lamprecht (10.1016/j.ejpb.2011.04.009_b0030) 2002; 84 Moser (10.1016/j.ejpb.2011.04.009_b0155) 2001; 73 Heurtault (10.1016/j.ejpb.2011.04.009_b0025) 2002; 19 Zhao (10.1016/j.ejpb.2011.04.009_b0135) 2009; 72 Cleek (10.1016/j.ejpb.2011.04.009_b0165) 1993; 10 Benech-Kieffer (10.1016/j.ejpb.2011.04.009_b0110) 2000; 13 Shokri (10.1016/j.ejpb.2011.04.009_b0125) 2001; 228 Müller (10.1016/j.ejpb.2011.04.009_b0080) 2007; 59 Prausnitz (10.1016/j.ejpb.2011.04.009_b0020) 2004; 3 Anton (10.1016/j.ejpb.2011.04.009_b0070) 2009; 25 Allard (10.1016/j.ejpb.2011.04.009_b0045) 2008; 130 Khalid (10.1016/j.ejpb.2011.04.009_b0055) 2006; 23 Zhai (10.1016/j.ejpb.2011.04.009_b0140) 2001; 14 Lamprecht (10.1016/j.ejpb.2011.04.009_b0035) 2004; 278 Radomska-Soukharev (10.1016/j.ejpb.2011.04.009_b0085) 2007; 59 Lamprecht (10.1016/j.ejpb.2011.04.009_b0060) 2006; 112 Peltier (10.1016/j.ejpb.2011.04.009_b0040) 2006; 23 Wu (10.1016/j.ejpb.2011.04.009_b0160) 2009; 26 Beduneau (10.1016/j.ejpb.2011.04.009_b0065) 2007; 28 Bouwstra (10.1016/j.ejpb.2011.04.009_b0010) 2002; 54 Hadgraft (10.1016/j.ejpb.2011.04.009_b0120) 2000; 200 Simon (10.1016/j.ejpb.2011.04.009_b0105) 2000; 13 Cevc (10.1016/j.ejpb.2011.04.009_b0015) 2004; 56 Benson (10.1016/j.ejpb.2011.04.009_b0130) 2005; 2 Zellmer (10.1016/j.ejpb.2011.04.009_b0145) 1995; 237 Béduneau (10.1016/j.ejpb.2011.04.009_b0050) 2008; 126 Schäfer-Korting (10.1016/j.ejpb.2011.04.009_b0075) 2007; 59
References_xml	– volume: 59 start-page: 427 year: 2007 end-page: 443 ident: b0075 article-title: Lipid nanoparticles for improved topical application of drugs for skin diseases publication-title: Adv. Drug Deliv. Rev. – volume: 200 start-page: 243 year: 2000 end-page: 247 ident: b0120 article-title: pH, pKa and dermal delivery publication-title: Int. J. Pharm. – volume: 10 start-page: 497 year: 1993 end-page: 506 ident: b0165 article-title: A new method for estimating dermal absorption from chemical exposure. 1. General approach publication-title: Pharm. Res. – volume: 14 start-page: 1 year: 2001 end-page: 10 ident: b0140 article-title: Effects of skin occlusion on percutaneous absorption: an overview publication-title: Skin Pharmacol. Appl. – volume: 103 start-page: 123 year: 2005 end-page: 136 ident: b0150 article-title: Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle–skin interaction publication-title: J. Controlled Release – volume: 130 start-page: 146 year: 2008 end-page: 153 ident: b0045 article-title: Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas publication-title: J. Controlled Release – volume: 363 start-page: 177 year: 2008 end-page: 182 ident: b0095 article-title: A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers publication-title: Int. J. Pharm. – volume: 2 start-page: 23 year: 2005 end-page: 33 ident: b0130 article-title: Transdermal drug delivery: penetration enhancement techniques publication-title: Curr. Drug Deliv. – volume: 126 start-page: 44 year: 2008 end-page: 49 ident: b0050 article-title: Brain targeting using novel lipid nanovectors publication-title: J. Controlled Release – volume: 28 start-page: 4978 year: 2007 end-page: 4990 ident: b0065 article-title: Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments publication-title: Biomaterials – volume: 352 start-page: 189 year: 2008 end-page: 196 ident: b0005 article-title: Evaluation of publication-title: Int. J. Pharm. – volume: 54 start-page: S41 year: 2002 end-page: S55 ident: b0010 article-title: Skin structure and mode of action of vesicles publication-title: Adv. Drug Deliv. Rev. – volume: 84 start-page: 59 year: 2002 end-page: 68 ident: b0030 article-title: New lipid nanocapsules exhibit sustained release properties for amiodarone publication-title: J. Controlled Release – volume: 19 start-page: 875 year: 2002 end-page: 880 ident: b0025 article-title: A novel phase inversion-based process for the preparation of lipid nanocarriers publication-title: Pharm. Res. – volume: 103 start-page: 61 year: 2005 end-page: 71 ident: b0100 article-title: Comparison of four different in vitro systems to study the reservoir capacity of the stratum corneum publication-title: J. Controlled Release – volume: 56 start-page: 675 year: 2004 end-page: 711 ident: b0015 article-title: Lipid vesicles and other colloids as drug carriers on the skin publication-title: Adv. Drug Deliv. Rev. – volume: 228 start-page: 99 year: 2001 end-page: 107 ident: b0125 article-title: The effect of surfactants on the skin penetration of diazepam publication-title: Int. J. Pharm. – volume: 215 start-page: 51 year: 2001 end-page: 56 ident: b0115 article-title: Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption publication-title: Int. J. Pharm. – volume: 23 start-page: 1243 year: 2006 end-page: 1250 ident: b0040 article-title: Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules publication-title: Pharm. Res. – volume: 73 start-page: 245 year: 2001 end-page: 253 ident: b0155 article-title: Enhanced skin permeation of a lipophilic drug using supersaturated formulations publication-title: J. Controlled Release – volume: 325 start-page: 140 year: 2006 end-page: 146 ident: b0090 article-title: Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations publication-title: Int. J. Pharm. – volume: 13 start-page: 324 year: 2000 end-page: 335 ident: b0110 article-title: Percutaneous absorption of sunscreens in vitro: interspecies comparison, skin models and reproducibility aspects publication-title: Skin Pharmacol. Appl. Skin Physiol. – volume: 26 start-page: 1995 year: 2009 end-page: 2001 ident: b0160 article-title: Drug delivery to the skin from sub-micron polymeric particle formulations: influence of particle size and polymer hydrophobicity publication-title: Pharm. Res. – volume: 72 start-page: 521 year: 2009 end-page: 528 ident: b0135 article-title: A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ publication-title: Eur. J. Pharm. Biopharm. – volume: 278 start-page: 407 year: 2004 end-page: 414 ident: b0035 article-title: Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment publication-title: Int. J. Pharm. – volume: 112 start-page: 208 year: 2006 end-page: 213 ident: b0060 article-title: Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition publication-title: J. Controlled Release – volume: 23 start-page: 752 year: 2006 end-page: 758 ident: b0055 article-title: Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors publication-title: Pharm. Res. – volume: 59 start-page: 522 year: 2007 end-page: 530 ident: b0080 article-title: Nanostructured lipid carriers (NLC) in cosmetic dermal products publication-title: Adv. Drug Deliv. Rev. – volume: 59 start-page: 411 year: 2007 end-page: 418 ident: b0085 article-title: Stability of lipid excipients in solid lipid nanoparticles publication-title: Adv. Drug Deliv. Rev. – volume: 25 start-page: 11413 year: 2009 end-page: 11419 ident: b0070 article-title: Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules publication-title: Langmuir – volume: 13 start-page: 229 year: 2000 end-page: 234 ident: b0105 article-title: The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations—an overview publication-title: Skin Pharmacol. Appl. Skin Physiol. – volume: 237 start-page: 176 year: 1995 end-page: 182 ident: b0145 article-title: Interaction of phosphatidylcholine liposomes with the human stratum corneum publication-title: Biochim. Biophys. Acta – volume: 3 start-page: 115 year: 2004 end-page: 124 ident: b0020 article-title: Current status and future potential of transdermal drug delivery publication-title: Nat. Rev. Drug Discov. – volume: 325 start-page: 140 year: 2006 ident: 10.1016/j.ejpb.2011.04.009_b0090 article-title: Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2006.06.012 – volume: 84 start-page: 59 year: 2002 ident: 10.1016/j.ejpb.2011.04.009_b0030 article-title: New lipid nanocapsules exhibit sustained release properties for amiodarone publication-title: J. Controlled Release doi: 10.1016/S0168-3659(02)00258-4 – volume: 10 start-page: 497 year: 1993 ident: 10.1016/j.ejpb.2011.04.009_b0165 article-title: A new method for estimating dermal absorption from chemical exposure. 1. General approach publication-title: Pharm. Res. doi: 10.1023/A:1018981515480 – volume: 59 start-page: 427 year: 2007 ident: 10.1016/j.ejpb.2011.04.009_b0075 article-title: Lipid nanoparticles for improved topical application of drugs for skin diseases publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2007.04.006 – volume: 126 start-page: 44 year: 2008 ident: 10.1016/j.ejpb.2011.04.009_b0050 article-title: Brain targeting using novel lipid nanovectors publication-title: J. Controlled Release doi: 10.1016/j.jconrel.2007.11.001 – volume: 2 start-page: 23 year: 2005 ident: 10.1016/j.ejpb.2011.04.009_b0130 article-title: Transdermal drug delivery: penetration enhancement techniques publication-title: Curr. Drug Deliv. doi: 10.2174/1567201052772915 – volume: 13 start-page: 324 issue: 6 year: 2000 ident: 10.1016/j.ejpb.2011.04.009_b0110 article-title: Percutaneous absorption of sunscreens in vitro: interspecies comparison, skin models and reproducibility aspects publication-title: Skin Pharmacol. Appl. Skin Physiol. doi: 10.1159/000029940 – volume: 23 start-page: 752 year: 2006 ident: 10.1016/j.ejpb.2011.04.009_b0055 article-title: Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors publication-title: Pharm. Res. doi: 10.1007/s11095-006-9662-5 – volume: 215 start-page: 51 year: 2001 ident: 10.1016/j.ejpb.2011.04.009_b0115 article-title: Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(00)00665-7 – volume: 237 start-page: 176 year: 1995 ident: 10.1016/j.ejpb.2011.04.009_b0145 article-title: Interaction of phosphatidylcholine liposomes with the human stratum corneum publication-title: Biochim. Biophys. Acta doi: 10.1016/0005-2736(95)00100-H – volume: 23 start-page: 1243 year: 2006 ident: 10.1016/j.ejpb.2011.04.009_b0040 article-title: Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules publication-title: Pharm. Res. doi: 10.1007/s11095-006-0022-2 – volume: 28 start-page: 4978 year: 2007 ident: 10.1016/j.ejpb.2011.04.009_b0065 article-title: Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments publication-title: Biomaterials doi: 10.1016/j.biomaterials.2007.05.014 – volume: 200 start-page: 243 year: 2000 ident: 10.1016/j.ejpb.2011.04.009_b0120 article-title: pH, pKa and dermal delivery publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(00)00402-6 – volume: 59 start-page: 411 year: 2007 ident: 10.1016/j.ejpb.2011.04.009_b0085 article-title: Stability of lipid excipients in solid lipid nanoparticles publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2007.04.004 – volume: 13 start-page: 229 year: 2000 ident: 10.1016/j.ejpb.2011.04.009_b0105 article-title: The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations—an overview publication-title: Skin Pharmacol. Appl. Skin Physiol. doi: 10.1159/000029928 – volume: 73 start-page: 245 year: 2001 ident: 10.1016/j.ejpb.2011.04.009_b0155 article-title: Enhanced skin permeation of a lipophilic drug using supersaturated formulations publication-title: J. Controlled Release doi: 10.1016/S0168-3659(01)00290-5 – volume: 130 start-page: 146 year: 2008 ident: 10.1016/j.ejpb.2011.04.009_b0045 article-title: Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas publication-title: J. Controlled Release doi: 10.1016/j.jconrel.2008.05.027 – volume: 103 start-page: 123 year: 2005 ident: 10.1016/j.ejpb.2011.04.009_b0150 article-title: Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle–skin interaction publication-title: J. Controlled Release doi: 10.1016/j.jconrel.2004.11.020 – volume: 56 start-page: 675 year: 2004 ident: 10.1016/j.ejpb.2011.04.009_b0015 article-title: Lipid vesicles and other colloids as drug carriers on the skin publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2003.10.028 – volume: 19 start-page: 875 year: 2002 ident: 10.1016/j.ejpb.2011.04.009_b0025 article-title: A novel phase inversion-based process for the preparation of lipid nanocarriers publication-title: Pharm. Res. doi: 10.1023/A:1016121319668 – volume: 59 start-page: 522 year: 2007 ident: 10.1016/j.ejpb.2011.04.009_b0080 article-title: Nanostructured lipid carriers (NLC) in cosmetic dermal products publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2007.04.012 – volume: 103 start-page: 61 year: 2005 ident: 10.1016/j.ejpb.2011.04.009_b0100 article-title: Comparison of four different in vitro systems to study the reservoir capacity of the stratum corneum publication-title: J. Controlled Release doi: 10.1016/j.jconrel.2004.11.013 – volume: 352 start-page: 189 year: 2008 ident: 10.1016/j.ejpb.2011.04.009_b0005 article-title: Evaluation of in vivo efficacy of topical formulations containing soybean extract publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.10.037 – volume: 54 start-page: S41 issue: Suppl. 1 year: 2002 ident: 10.1016/j.ejpb.2011.04.009_b0010 article-title: Skin structure and mode of action of vesicles publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/S0169-409X(02)00114-X – volume: 72 start-page: 521 year: 2009 ident: 10.1016/j.ejpb.2011.04.009_b0135 article-title: A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2009.03.002 – volume: 112 start-page: 208 year: 2006 ident: 10.1016/j.ejpb.2011.04.009_b0060 article-title: Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition publication-title: J. Controlled Release doi: 10.1016/j.jconrel.2006.02.014 – volume: 25 start-page: 11413 year: 2009 ident: 10.1016/j.ejpb.2011.04.009_b0070 article-title: Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules publication-title: Langmuir doi: 10.1021/la901565q – volume: 14 start-page: 1 year: 2001 ident: 10.1016/j.ejpb.2011.04.009_b0140 article-title: Effects of skin occlusion on percutaneous absorption: an overview publication-title: Skin Pharmacol. Appl. doi: 10.1159/000056328 – volume: 26 start-page: 1995 year: 2009 ident: 10.1016/j.ejpb.2011.04.009_b0160 article-title: Drug delivery to the skin from sub-micron polymeric particle formulations: influence of particle size and polymer hydrophobicity publication-title: Pharm. Res. doi: 10.1007/s11095-009-9915-1 – volume: 3 start-page: 115 year: 2004 ident: 10.1016/j.ejpb.2011.04.009_b0020 article-title: Current status and future potential of transdermal drug delivery publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd1304 – volume: 278 start-page: 407 year: 2004 ident: 10.1016/j.ejpb.2011.04.009_b0035 article-title: Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2004.03.018 – volume: 228 start-page: 99 year: 2001 ident: 10.1016/j.ejpb.2011.04.009_b0125 article-title: The effect of surfactants on the skin penetration of diazepam publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(01)00805-5 – volume: 363 start-page: 177 year: 2008 ident: 10.1016/j.ejpb.2011.04.009_b0095 article-title: A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2008.07.017
SSID	ssj0004758
Score	2.4179897
Snippet	Lipid nanocarriers are efficient transdermal drug delivery systems while polymeric nanoparticles are better suited for local effects on the skin. Lipid... Lipid nanocapsules (LNC) are colloidal carriers providing controlled release profiles and improved bioavailability for many drug substances and diverse...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	36
SubjectTerms	Administration, Cutaneous Animals Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - analysis Anti-Inflammatory Agents, Non-Steroidal - chemistry Anti-Inflammatory Agents, Non-Steroidal - pharmacology Cellulose - analogs & derivatives Cellulose - chemistry Delayed-Action Preparations Drug Carriers - chemistry Drug Compounding Drug Delivery Systems Drug Evaluation, Preclinical Ear - physiology Ibuprofen - administration & dosage Ibuprofen - analysis Ibuprofen - chemistry Ibuprofen - pharmacology Lipid nanocapsules Lipids - chemistry Nanocapsules - chemistry Nanocarriers Nanoparticles - chemistry Nanostructures - chemistry Particle Size Permeability Polyethylene Glycols - chemistry Polymer nanoparticles Polymers - chemistry Skin Skin - metabolism Stearic Acids - chemistry Surface-Active Agents - chemistry Swine Transdermal
Title	Lipid nanocapsules for dermal application: A comparative study of lipid-based versus polymer-based nanocarriers
URI	https://dx.doi.org/10.1016/j.ejpb.2011.04.009 https://www.ncbi.nlm.nih.gov/pubmed/21558002 https://www.proquest.com/docview/885909615
Volume	79
WOSCitedRecordID	wos000295427600006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-3441 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004758 issn: 0939-6411 databaseCode: AIEXJ dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELb2wYEL4k15rHxAe8mmysOJHW4VWgSIXVWioN6i2HG0rUJSNe1q--f4bczESZOy6gqQuESV2zza7-t4Zuz5hpC3gcy41FFge67UEKDI1I7AFtsKpm6mZCDTup3P9y_88lJMp9H44OBnWwtznfOiEDc30eK_Qg1jADaWzv4F3NuLwgC8BtDhCLDD8Y-Ax27UqVUkBcxSEALnulZcsFI0wbnVW7A2RemqJ_9dtQrTOV7DxhkutXDfxrrCbg6bH3rZDJrLL7HdXbU3ud84uourLm1uFKHlrNwZ7NagUp3bF-UKIgJdLxSByUmsi-Fo2CWtcdXBmMpZV2aEupFgu02eYZRn_WQGZmejfjLjdpWNSVX6kR2yxihrY6gF922fGdGs1pKbtjQ7jDVm2Q97E7xR87o1dZgsxnyo5wvZSLuisHrUTZTb7Ytf8YnwgVBvD12mQ3Ls8SACq3o8-nQ-_dxV5vK6Q-z2GzRlW2aH4e932uca7Qt9ahdo8pA8aGIXOjKce0QOdPGYnI4NkpszOulq-aozekrHnSz65gkpa2LSPjEpEJMaYtIeMd_REe3Rkta0pGVGe7SkhpZ0h5a0T8un5NuH88n7j3bT7gMNg7uyhRcpjynuaOkEWrhY9OxwGSRKAtquK53Uy5xU-SFPWKjQ_QqZkBLekcJ1U_8ZOSrKQr8gFJz8LOOBK8OMM6ZS4ScK4gQtZcqEx6IBcdtfOlaNFj62ZMnjdtPjPEZ0YkQndlgM6AyItT1nYZRg7vx00AIYN76s8VFj4Nud59EW7RgMPa7eJYUu11UsRBBhf6ZgQJ4bFmwfA9z2AAO_l_9401fkfvdnfE2OVsu1fkPuqevVrFqekEM-FScNs38BoYXd0A
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lipid+nanocapsules+for+dermal+application%3A+A+comparative+study+of+lipid-based+versus+polymer-based+nanocarriers&rft.jtitle=European+journal+of+pharmaceutics+and+biopharmaceutics&rft.au=Abdel-Mottaleb%2C+Mona+M.A.&rft.au=Neumann%2C+Dirk&rft.au=Lamprecht%2C+Alf&rft.date=2011-09-01&rft.pub=Elsevier+B.V&rft.issn=0939-6411&rft.eissn=1873-3441&rft.volume=79&rft.issue=1&rft.spage=36&rft.epage=42&rft_id=info:doi/10.1016%2Fj.ejpb.2011.04.009&rft.externalDocID=S0939641111001512
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0939-6411&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0939-6411&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0939-6411&client=summon